流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识

2017-04-05 中国抗癌协会血液肿瘤专业委员会 中华病理学杂志,2017,46(04):217-222.

淋巴瘤是临床上诊断难度较大的一类疾病,需要综合血液病理学(包括组织和细胞形态学、免疫表型、遗传学和分子生物学)与临床特征才能做出精确诊断。流式细胞学(FCM)免疫分型作为与免疫组织化学相补的诊断方法,以其快速、客观、定量及多参数分析等独特优势,在淋巴瘤诊断方面发挥着不可替代的作用 。为了提高淋巴瘤的诊断和治疗监测水平,规范我国对此类疾病的诊治程序,中国抗癌协会血液肿瘤专业委员会组织国内相关的流式、

中文标题:

流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识

发布日期:

2017-04-05

简要介绍:

淋巴瘤是临床上诊断难度较大的一类疾病,需要综合血液病理学(包括组织和细胞形态学、免疫表型、遗传学和分子生物学)与临床特征才能做出精确诊断。流式细胞学(FCM)免疫分型作为与免疫组织化学相补的诊断方法,以其快速、客观、定量及多参数分析等独特优势,在淋巴瘤诊断方面发挥着不可替代的作用 。为了提高淋巴瘤的诊断和治疗监测水平,规范我国对此类疾病的诊治程序,中国抗癌协会血液肿瘤专业委员会组织国内相关的流式、血液肿瘤和病理专家经过多次讨论,结合国外已有文献资料和国内临床经验,制订了流式检测技术在淋巴瘤诊断中应用的专家共识。本共识旨在推动流式检测技术在淋巴瘤诊疗中的应用,促进多学科合作在淋巴瘤诊疗中的发展。

 

拓展指南:淋巴瘤相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=8487f1c001ae6327, title=流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识, enTitle=, guiderFrom=中华病理学杂志,2017,46(04):217-222., authorId=null, author=, summary=淋巴瘤是临床上诊断难度较大的一类疾病,需要综合血液病理学(包括组织和细胞形态学、免疫表型、遗传学和分子生物学)与临床特征才能做出精确诊断。流式细胞学(FCM)免疫分型作为与免疫组织化学相补的诊断方法,以其快速、客观、定量及多参数分析等独特优势,在淋巴瘤诊断方面发挥着不可替代的作用 。为了提高淋巴瘤的诊断和治疗监测水平,规范我国对此类疾病的诊治程序,中国抗癌协会血液肿瘤专业委员会组织国内相关的流式、, cover=, journalId=null, articlesId=null, associationId=1385, associationName=中国抗癌协会血液肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Wed Apr 05 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>淋巴瘤是临床上诊断难度较大的一类疾病,需要综合血液病理学(包括组织和细胞形态学、免疫表型、遗传学和分子生物学)与临床特征才能做出精确诊断。流式细胞学(FCM)免疫分型作为与免疫组织化学相补的诊断方法,以其快速、客观、定量及多参数分析等独特优势,在淋巴瘤诊断方面发挥着不可替代的作用 。为了提高淋巴瘤的诊断和治疗监测水平,规范我国对此类疾病的诊治程序,中国抗癌协会血液肿瘤专业委员会组织国内相关的流式、血液肿瘤和病理专家经过多次讨论,结合国外已有文献资料和国内临床经验,制订了流式检测技术在淋巴瘤诊断中应用的专家共识。本共识旨在推动流式检测技术在淋巴瘤诊疗中的应用,促进多学科合作在淋巴瘤诊疗中的发展。 </P> <P> </P>拓展指南:<strong>与<font color=red>淋巴瘤</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=85cc91c001a253b7" title="NCCN临床实践指南:原发性皮肤B细胞淋巴瘤(2017.V2)" target=_blank>NCCN临床实践指南:原发性皮肤B细胞淋巴瘤(2017.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=3fe581c001a11139" title="长春碱类药物治疗恶性淋巴瘤中国专家共识(2017)" target=_blank>长春碱类药物治疗恶性淋巴瘤中国专家共识(2017)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6e14b1c0013850f6" title="NCCN临床实践指南:B细胞淋巴瘤(2017.V2)" target=_blank>NCCN临床实践指南:B细胞淋巴瘤(2017.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=32b2b1c001382847" title="NCCN临床实践指南:T细胞淋巴瘤(2017.V2)" target=_blank>NCCN临床实践指南:T细胞淋巴瘤(2017.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4da6b1c001382ad9" title="【NCCN指南专题】:关注淋巴瘤,了解最新的指南更新" target=_blank>【NCCN指南专题】:关注淋巴瘤,了解最新的指南更新</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E6%B7%8B%E5%B7%B4%E7%98%A4" target=_blank>有关淋巴瘤更多指南</a></ul>, tagList=[TagDto(tagId=55463, tagName=流式细胞学), TagDto(tagId=1170, tagName=非霍奇金淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=69, categoryName=检验, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5338, appHits=218, showAppHits=0, pcHits=3850, showPcHits=1919, likes=165, shares=8, comments=6, approvalStatus=1, publishedTime=Sat Jul 29 19:52:44 CST 2017, publishedTimeString=2017-04-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Jul 29 19:52:44 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 12:55:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识)])
流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=228794, encodeId=ec84228e94a6, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Tue Aug 01 10:50:12 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228397, encodeId=dd1922839e86, content=学习了,继续努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Mon Jul 31 09:11:26 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228375, encodeId=8d202283e551, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jul 31 09:05:34 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-08-01 139****0239

    henhao

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=228794, encodeId=ec84228e94a6, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Tue Aug 01 10:50:12 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228397, encodeId=dd1922839e86, content=学习了,继续努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Mon Jul 31 09:11:26 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228375, encodeId=8d202283e551, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jul 31 09:05:34 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-07-31 139****9672

    学习了,继续努力

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=228794, encodeId=ec84228e94a6, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Tue Aug 01 10:50:12 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228397, encodeId=dd1922839e86, content=学习了,继续努力, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Mon Jul 31 09:11:26 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228375, encodeId=8d202283e551, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jul 31 09:05:34 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-07-31 1e0e5697m83(暂无匿称)

    henhao

    0